原发性免疫性血小板减少症患者PAI-1基因的多态性
| 作者: |
1叶小翠,
2张学亚
1 福建医科大学附属第二医院检验科，福建 泉州 362000 2 福建医科大学附属第二医院血液科，福建 泉州 362000 |
| 通讯: |
张学亚
Email: jakey3456@sina.com |
| DOI: | 10.3978/j.issn.2095-6959. 2018.12.010 |
摘要
目的：通过分析原发性免疫性血小板减少症(primary immune thrombocytopenia，ITP)患者的纤维蛋白溶解酶活化物抑制剂-1(fibrinolytic enzyme activator inhibitor-1，PAI-1)基因多态性，探讨其临床意义。方法：研究46例ITP患者，以明确继发于系统性红斑狼疮(systemic lupus erythematosus， SLE)的血小板减少症患者42例和明确继发于感染的血小板减少症患者33例分别作为对照。采用荧光染色原位杂交测序法检测PAI-1基因多态性。结果：46例ITP患者中，33例PAI-1基因表型为4G4G型，9例为4G5G型，4例为5G5G型。42例继发于SLE的血小板减少症患者中，30例为4G4G型，5例为4G5G型，7例为5G5G型。继发于感染的血小板减少症患者中，3例为4G4G型，23例为4G5G型，7例为5G5G型。ITP患者PAI-1基因4G4G型与继发于SLE的患者PAI-1基因4G4G型检出率相似，而与继发于感染患者的PAI-1基因4G4G型之间差异有统计学意义(P<0.05)。结论：ITP和继发于SLE的血小板减少症患者PAI-1基因多呈4G4G型，而继发于感染的血小板减少症患者多呈非4G4G型。ITP患者检测PAI-1基因多态性将有望评估其血栓风险及向SLE发展的可能性。
关键词：
血小板减少；免疫性；纤维蛋白溶解酶活化物抑制剂-1；基因多态性
Polymorphism of PAI-1 gene in patients with primary immune thrombocytopenia
CorrespondingAuthor: ZHANG Xueya Email: jakey3456@sina.com
DOI: 10.3978/j.issn.2095-6959. 2018.12.010
Abstract
Objective: To investigate the clinical significance of fibrinolytic enzyme activator inhibitor-1 (PAI-1) gene polymorphism in patients with primary immune thrombocytopenia (ITP). Methods: Forty-six patients with ITP were enrolled to identify 42 patients with thrombocytopenia secondary to systemic lupus erythematosus (SLE) and 33 patients with thrombocytopenia secondary to infection as control. The PAI-1 gene polymorphism was detected by fluorescence staining in situ hybridization sequencing. Results: Of the 46 patients with ITP, 33 had a PAI-1 gene phenotype of 4G4G, 9 were 4G5G, and 4 were 5G5G. Of the 42 patients with thrombocytopenia secondary to SLE, 30 were 4G4G, 5 were 4G5G, and 7 were 5G5G. Among the patients with thrombocytopenia secondary to infection, 3 were 4G4G, 23 were 4G5G, and 7 were 5G5G. The PAI-1 gene 4G4G type was similar to the PEI-1 gene 4G4G type in patients with ITP, but it was statistically different from the PAI-1 gene 4G4G type secondary to infected patients (P<0.05). Conclusion: The PAI-1 gene of ITP and thrombocytopenia secondary to SLE is mostly 4G4G, while the patients with secondary thrombocytopenia are mostly non-4G4G. Detection of the PAI-1 gene polymorphism in patients with ITP is expected to assess the risk of thrombosis and the potential for progression to SLE.
Keywords：
thrombocytopenia; immunity; fibrinolytic enzyme activator inhibitor-1; gene polymorphism